Read the latest news about the California stem cell agency on our new platform. The link below will take you there. You can subscribe free today by clicking on the button at the end of the article below. Don't miss any of the latest doings at the $12 billion California Institute for Regenerative Medicine (CIRM). The Los Angeles Times says the California Stem Cell Report is "indispensable" reading. More than 3 million page views can't be wrong.
Friday, December 17, 2021
Friday, August 13, 2021
Bluebird bio's $1.8 Million Setback on Gene Therapy: Is It a Growing Sign of Rejection of Reimbursement Profit Models?
Sunday, June 13, 2021
Subscribe Free Today to the California Stem Cell Report -- - The Most Comprehensive Source for the Ins and Outs of California's $12 Billion Stem Cell Program
Don't miss important fresh news and information about California's $12 billion stem cell research agency. It is charting a new course with new opportunities and significant changes in direction, including a greater emphasis on the fast-growing gene therapy field.
The changes already mean a lot for patients, researchers and policymakers and will have an even greater impact in the next several years. Tracking the agency's affairs is not easy, but you can find what you need on the The California Stem Cell Report.
Dubbed "indispensable" and "authoritative" in the Los Angeles Times, the Report is the only regular, independent source of news and information dealing with the California Institute for Regenerative Medicine (CIRM).
It is news that can be found nowhere else. Plus it is comprehensive. More than 5,000 items have been published since CIRM was created in 2004.
You can subscribe free to the California Stem Cell Report on its new platform by clicking on the "Subscribe Today!" box on the upper right of this page. Or just go to one of the following recent stories and click on the subscribe button.California Stem Cell Agency Withholds $5.8 Million from Orchard in Bubble-Baby Flap; Money to Go to New Effort Involving Compassionate Use
Monday, May 24, 2021
Read All About It: Bubble Babies Hit by Suspension of Trial for Genetic Cure; California Taxpayers Paying for Trial
"Indispensable" is what the Los Angeles Times this morning called this blog, the California Stem Cell Report.
The comment came in a story that was triggered by our coverage of the Orchard-CIRM-UCLA bubble baby clinical trial, which was shoved aside by Orchard Therapeutics for financial reasons. That leaves a bunch of children out in the cold as far as the genetic treatment is concerned.
UCLA says the treatment has saved the lives of more than 50 persons.
Below is a list of the Orchard stories that we have carried on our new platform since we unearthed the issue on May 11. You can subscribe free to articles on our new home by clicking on the subscribe button in stories on the new platform. Subscribe today.
Here is the list.
Sunday, April 04, 2021
Essential Reading on California's Ground-Breaking, $12 Billion, Stem Cell/Gene Therapy Research Program
Don't miss out on news and information on the $12 billion California stem cell agency.
Its activities affect the lives of thousands of people and have the potential to affect the lives of millions of more. Not to mention that it is venturing into new areas of health policy and research.
Subscribe today to the California Stem Cell Report on its new platform. You can do so by clicking here and tapping the subscribe button. Plus it's free.
Cited as “indispensable” in the Los Angeles Times, the California Stem Cell Report is the only independent voice regularly reporting on the activities of the California Institute for Regenerative Medicine (CIRM), as the stem cell agency is officially known. In 2012, the Institute of Medicine invited the publisher of this site to testify during its $700,000 evaluation of CIRM.
This report has covered CIRM since its inception in 2004 and has published more than 5,000 items and attracted more than 3 million page views.
It is essential reading if you have something at stake in what CIRM does and how it spends its money.
Here are links to recent articles on the California Stem Cell Report's new platform.
California's Sickle Cell Surge: Researchers Tackle Disease with First-Ever, Gene-Editing Clinical Trial
Friday, March 26, 2021
What Does 'Unlikely' Mean?
The talk at the California stem cell agency this week was of ”boiling the ocean,” the meaning of “unlikely” and “DEI.” All of which involves how $5.5 billion in taxpayer dollars will be used over the next decade or so....
Read all about it on the new platform for the California Stem Cell Report. And please subscribe on the new site to keep seeing the most complete and independent source of information on the doings at the state's $12 billion therapy development enterprise.
Thursday, March 18, 2021
CIRM directors tomorrow take up the matter of how the agency chooses the judges of applications for billions of California stem cell research dollars. You can read more about what's in store on the new platform of the California Stem Cell Report.
You can also make sure you don't miss any of the news by subscribing free. It's easy. Just click on the subscribe button when you go to the link below.
Looking at how scientists are chosen to score grant applications
The California stem cell agency has released its plans to revise the process of choosing the folks who make the de facto decisions on billions of dollars in research awards.
The revisions grew out of a meeting last month of the governing board of the $12 billion agency, officially called the California Institute for Regenerative Medicine (CIRM).
Some directors sought more diversity among as many as 300 scientists who are tapped to review applications for awards. One director sought assurances that the process would lead to the selection of the most talented scientists, ones who also could be counted on work positively with others during the review process....